Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for F-star Therapeutics, Inc. (FSTX : NSDQ)
 
 • Company Description   
F-star Therapeutics Inc. is a clinical-stage biopharmaceutical company. It engages in developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. F-star Therapeutics Inc., formerly known as Spring Bank Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.

Number of Employees: 88

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.33 Daily Weekly Monthly
20 Day Moving Average: 149,571 shares
Shares Outstanding: 21.56 (millions)
Market Capitalization: $50.23 (millions)
Beta: 1.86
52 Week High: $9.71
52 Week Low: $2.07
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -28.09% -21.50%
12 Week -33.05% -27.64%
Year To Date -53.59% -45.02%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
Eddeva B920 Babraham Research Campus
-
CAMBRIDGE,X0 CB22 3AT
GBR
ph: 44-12-2349-7400
fax: 508-381-0347
lindsey.trickett@fstar.com http://www.f-star.com
 
 • General Corporate Information   
Officers
Eliot Forster - President; Chief Executive Officer and Chairman
Darlene Deptula-Hicks - Chief Financial Officer and Treasurer
David Arkowitz - Director
Edward Benz - Director
Nessan Bermingham - Director

Peer Information
F-star Therapeutics, Inc. (CORR.)
F-star Therapeutics, Inc. (RSPI)
F-star Therapeutics, Inc. (CGXP)
F-star Therapeutics, Inc. (BGEN)
F-star Therapeutics, Inc. (GTBP)
F-star Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 30315R107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 21.56
Most Recent Split Date: 11.00 (0.25:1)
Beta: 1.86
Market Capitalization: $50.23 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.64 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.39 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.57
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 47.22%
vs. Previous Quarter: -221.28%
Sales Growth
vs. Year Ago Period: -12.55%
vs. Previous Quarter: -85.42%
ROE
03/31/22 - -36.13
12/31/21 - -39.37
09/30/21 - -67.22
ROA
03/31/22 - -28.30
12/31/21 - -30.34
09/30/21 - -50.28
Current Ratio
03/31/22 - 6.11
12/31/21 - 6.98
09/30/21 - 8.62
Quick Ratio
03/31/22 - 6.11
12/31/21 - 6.98
09/30/21 - 8.62
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -164.01
12/31/21 - -149.55
09/30/21 - -1,170.40
Book Value
03/31/22 - 4.09
12/31/21 - 4.70
09/30/21 - 4.37
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.14
12/31/21 - 0.13
09/30/21 - 0.14
Debt-to-Capital
03/31/22 - 12.12
12/31/21 - 11.29
09/30/21 - 12.11
 

Powered by Zacks Investment Research ©